{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-091315","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.345917+00:00","generated_at":"2026-05-31T08:24:47.273725+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope","bullets":["Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.","Amended and Restated Agreement clarifies definitions of 'gross revenue' with specified deductions.","Covered Products now explicitly include CytoSorb, VetResQ, ECOS-300CY, and certain DrugSorb versions.","Agreement dated August 16, 2024, amends the original 2003 Letter Agreement with ROKK."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-091315","json":"https://secwatch.observer/filing/0001104659-24-091315.json","markdown":"https://secwatch.observer/filing/0001104659-24-091315.md","text":"https://secwatch.observer/filing/0001104659-24-091315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/0001104659-24-091315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/tm2422183-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:24:47.273725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}